Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

$21.5 Million Series D Round Gives Promedior Runway To Advance Lead Program In Two Fibrotic Indications

This article was originally published in The Pink Sheet Daily

Executive Summary

Recent deal-making has brought larger, deeper-pocketed players into the IPF space, but Promedior still likes its approach of going it alone with Pentraxin-2-based therapies in fibrotic disease.

You may also be interested in...



Bristol’s Fibrotic Game Plan: Promedior Acquisition Hinges On Phase II Results

Bristol’s third deal in anti-fibrosis field in past year could give it intravenous, disease-modifying candidate for myelofibrosis and idiopathic fibrosis.

After Pirfenidone: Broad Competition To Bring First Therapy For Underlying Cause Of IPF To Market

In the latest in “The Pink Sheet”’s market snapshot series, InterMune continues to work on getting pirfenidone approved in the U.S., while several companies are developing next-stage therapies for IPF.

Biogen Idec Buys Stromedix, Bringing IPF Candidate Full Circle

Started by a former Biogen executive, Stromedix licensed STX-100 from Biogen and developed it into an attractive candidate in an area the reshaped big biotech wants to pursue.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS073859

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel